Sci Rep
August 17, 2023
Anne Buot, Cecile Pallares, Alina Oganesyan et al.
28 citations
Classic psychedelics were the only substances reported to reduce obsessive compulsive disorder (OCD) symptoms in a retrospective online survey of 174 people who used psychoactive drugs. Symptom reduction was linked to the intensity of acute effects, which correlated with dose. Therapeutic effects lasted from weeks to months, but no factor predicted their persistence. Frequency of subsequent use was predicted by the magnitude and persistence of the effect, though overall use was limited. The findings support the possibility that classic psychedelics can reduce OCD symptoms, but careful evaluation of effect persistence is still needed.
BMC psychiatry
January 26, 2024
Laetitia Vanderijst, Felix Hever, Anne Buot et al.
11 citations
A proposed clinical trial will test whether adding psilocybin-assisted therapy to inpatient rehabilitation for severe alcohol use disorder is feasible and effective. In a double-blind, randomized, placebo-controlled phase II trial, 62 participants aged 21–64 will receive either a high dose (30 mg) or an active placebo dose (5 mg) of psilocybin alongside a brief psychotherapy based on acceptance and commitment therapy. The main outcome is the difference in heavy drinking days from baseline to four weeks after hospital discharge. Secondary outcomes include drinking behavior up to six months, mental health symptoms, neuroplasticity, and cognitive mechanisms. The trial is registered as EudraCT 2022-002369-14 and NCT06160232.
Research Square (Research Square)
January 4, 2024
Laetitia Vanderijst, Felix Hever, Anne Buot et al.
A proposed double-blind, randomized, placebo-controlled phase II trial will test whether adding psilocybin-assisted therapy to a 4-week inpatient rehabilitation program for severe alcohol use disorder is feasible and clinically effective. Sixty-two participants aged 21–64 years will receive either a high dose (30 mg) or an active placebo dose (5 mg) of psilocybin, both paired with a brief acceptance and commitment therapy intervention. The primary clinical outcome is the change in percentage of heavy drinking days from baseline to four weeks after hospital discharge. Secondary outcomes include drinking behavior up to six months, symptoms of depression and anxiety, neuroplasticity, and changes in neurocognitive systems linked to addiction.